Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
Authors
Keywords
Metastatic melanoma, Ipilimumab, Immunotherapy, Toxicity, Interleukin-6, Autoimmunity, Immune-related adverse events
Journal
Journal of Translational Medicine
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-04-11
DOI
10.1186/s12967-018-1467-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment
- (2016) C. Bender et al. ANNALS OF ONCOLOGY
- Circulating Beta-2 Microglobulin and Risk of Cancer: The Atherosclerosis Risk in Communities Study (ARIC)
- (2016) A. E. Prizment et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: A snapshot of IL-6 mediated involvement
- (2016) Rashmi Bharti et al. CANCER LETTERS
- The SRF-YAP-IL6 axis promotes breast cancer stemness
- (2016) Tackhoon Kim et al. CELL CYCLE
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Δ133p53 isoform and its mouse analogue Δ122p53 promote invasion and metastasis involving pro-inflammatory molecules interleukin-6 and CCL2
- (2016) I Roth et al. ONCOGENE
- Self-renewal of CD133hi cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer
- (2016) Pasquale Sansone et al. Nature Communications
- Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
- (2015) Santiago Zelenay et al. CELL
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
- (2015) M. Freeman-Keller et al. CLINICAL CANCER RESEARCH
- Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab
- (2015) S. Valpione et al. EUROPEAN JOURNAL OF CANCER
- C-Reactive Protein As a Marker of Melanoma Progression
- (2015) Shenying Fang et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Ipilimumab in the real world
- (2015) Saif S. Ahmad et al. MELANOMA RESEARCH
- IL6 Mediates Immune and Colorectal Cancer Cell Cross-talk via miR-21 and miR-29b
- (2015) S. A. A. Patel et al. MOLECULAR CANCER RESEARCH
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3′-diindolylmethane in ovarian cancer cells
- (2015) Minghua Zou et al. CELLULAR ONCOLOGY
- Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
- (2015) Aitziber Buqué et al. OncoImmunology
- A prospective evaluation of the role of Vascular Endothelial Growth Factor (VEGF) and the immune system in stage III/IV melanoma
- (2015) Nicole Marie Agostino et al. SpringerPlus
- Economic Burden Associated with Adverse Events in Patients with Metastatic Melanoma
- (2015) Bhakti Arondekar et al. Journal of Managed Care & Specialty Pharmacy
- Correcting for Optimistic Prediction in Small Data Sets
- (2014) Gordon C. S. Smith et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies
- (2014) C. Lebbe et al. ANNALS OF ONCOLOGY
- Interleukin-6 and its receptors: A highly regulated and dynamic system
- (2014) Janina Wolf et al. CYTOKINE
- Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations
- (2014) Desirée Schubert et al. NATURE MEDICINE
- Somatic Mutations and Immunotherapy Outcome with CTLA-4 Blockade in Melanoma
- (2014) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)
- (2013) D. McDermott et al. ANNALS OF ONCOLOGY
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- The Use of Cytokines and Chemokines in the Cancer Immunotherapy
- (2013) Amedeo Amedei et al. Recent Patents on Anti-Cancer Drug Discovery
- Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma
- (2012) Lise Hoejberg et al. MELANOMA RESEARCH
- Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis
- (2012) Victor Barzey et al. JOURNAL OF MEDICAL ECONOMICS
- Beta2-Microglobulin Can Be a Disease Activity Marker in Systemic Lupus Erythematosus
- (2010) Hyoun-Ah Kim et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- Biomarkers in melanoma
- (2009) H. Gogas et al. ANNALS OF ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started